Cargando…
Severe Fatal Mucormycosis in a Patient with Chronic Lymphocytic Leukaemia Treated with Zanubrutinib: A Case Report and Review of the Literature
Severe mucormycosis is a fatal disease rarely complicating chronic lymphoproliferative disorders. We present a fulminant and fatal case of a 74-year-old Caucasian woman suffering from CLL treated with second-generation BTK inhibitor zanubrutinib. After a first septic episode a month prior, originati...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10529318/ https://www.ncbi.nlm.nih.gov/pubmed/37754514 http://dx.doi.org/10.3390/curroncol30090599 |
_version_ | 1785111374344486912 |
---|---|
author | Maggioni, Giuseppe Fedrigo, Marny Visentin, Andrea Carturan, Elisa Ruocco, Valeria Trentin, Livio Alaibac, Mauro Angelini, Annalisa |
author_facet | Maggioni, Giuseppe Fedrigo, Marny Visentin, Andrea Carturan, Elisa Ruocco, Valeria Trentin, Livio Alaibac, Mauro Angelini, Annalisa |
author_sort | Maggioni, Giuseppe |
collection | PubMed |
description | Severe mucormycosis is a fatal disease rarely complicating chronic lymphoproliferative disorders. We present a fulminant and fatal case of a 74-year-old Caucasian woman suffering from CLL treated with second-generation BTK inhibitor zanubrutinib. After a first septic episode a month prior, originating from the lung with later systemic involvement by an unidentified agent and treated with large-spectrum antibiotics and fluconazonle, a slow-onset enlarging tender warm and erythematous nodular swollen cutaneous lesion appeared in her lower limbs and spread subsequently to her upper limbs, progressing towards central ulceration with a necrotic core. Suspecting a mycotic dissemination from an unknown agent, a skin punch biopsy was performed, and intraconazole was started. Due to spread of the skin lesions, the patient was hospitalized and intravenous liposomal ampthotericin B was started. Histopathology showed an atypical sporangium-rich mycotic angioinvasion of the small vessels. Only the increase of BDG and GM could corroborate the hypothesis of mycotic infection. However, long-term CLL, immunosuppressive therapies, neutropenia, and prior use of azoles and other antimycotic agents were risk factors for mucormycosis; BTK inhibitor could also be added as another novel risk factor. Despite all therapeutic efforts, the patient died. Post-mortem molecular exams confirmed the diagnosis of disseminated mucormycosis. |
format | Online Article Text |
id | pubmed-10529318 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105293182023-09-28 Severe Fatal Mucormycosis in a Patient with Chronic Lymphocytic Leukaemia Treated with Zanubrutinib: A Case Report and Review of the Literature Maggioni, Giuseppe Fedrigo, Marny Visentin, Andrea Carturan, Elisa Ruocco, Valeria Trentin, Livio Alaibac, Mauro Angelini, Annalisa Curr Oncol Case Report Severe mucormycosis is a fatal disease rarely complicating chronic lymphoproliferative disorders. We present a fulminant and fatal case of a 74-year-old Caucasian woman suffering from CLL treated with second-generation BTK inhibitor zanubrutinib. After a first septic episode a month prior, originating from the lung with later systemic involvement by an unidentified agent and treated with large-spectrum antibiotics and fluconazonle, a slow-onset enlarging tender warm and erythematous nodular swollen cutaneous lesion appeared in her lower limbs and spread subsequently to her upper limbs, progressing towards central ulceration with a necrotic core. Suspecting a mycotic dissemination from an unknown agent, a skin punch biopsy was performed, and intraconazole was started. Due to spread of the skin lesions, the patient was hospitalized and intravenous liposomal ampthotericin B was started. Histopathology showed an atypical sporangium-rich mycotic angioinvasion of the small vessels. Only the increase of BDG and GM could corroborate the hypothesis of mycotic infection. However, long-term CLL, immunosuppressive therapies, neutropenia, and prior use of azoles and other antimycotic agents were risk factors for mucormycosis; BTK inhibitor could also be added as another novel risk factor. Despite all therapeutic efforts, the patient died. Post-mortem molecular exams confirmed the diagnosis of disseminated mucormycosis. MDPI 2023-09-07 /pmc/articles/PMC10529318/ /pubmed/37754514 http://dx.doi.org/10.3390/curroncol30090599 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Maggioni, Giuseppe Fedrigo, Marny Visentin, Andrea Carturan, Elisa Ruocco, Valeria Trentin, Livio Alaibac, Mauro Angelini, Annalisa Severe Fatal Mucormycosis in a Patient with Chronic Lymphocytic Leukaemia Treated with Zanubrutinib: A Case Report and Review of the Literature |
title | Severe Fatal Mucormycosis in a Patient with Chronic Lymphocytic Leukaemia Treated with Zanubrutinib: A Case Report and Review of the Literature |
title_full | Severe Fatal Mucormycosis in a Patient with Chronic Lymphocytic Leukaemia Treated with Zanubrutinib: A Case Report and Review of the Literature |
title_fullStr | Severe Fatal Mucormycosis in a Patient with Chronic Lymphocytic Leukaemia Treated with Zanubrutinib: A Case Report and Review of the Literature |
title_full_unstemmed | Severe Fatal Mucormycosis in a Patient with Chronic Lymphocytic Leukaemia Treated with Zanubrutinib: A Case Report and Review of the Literature |
title_short | Severe Fatal Mucormycosis in a Patient with Chronic Lymphocytic Leukaemia Treated with Zanubrutinib: A Case Report and Review of the Literature |
title_sort | severe fatal mucormycosis in a patient with chronic lymphocytic leukaemia treated with zanubrutinib: a case report and review of the literature |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10529318/ https://www.ncbi.nlm.nih.gov/pubmed/37754514 http://dx.doi.org/10.3390/curroncol30090599 |
work_keys_str_mv | AT maggionigiuseppe severefatalmucormycosisinapatientwithchroniclymphocyticleukaemiatreatedwithzanubrutinibacasereportandreviewoftheliterature AT fedrigomarny severefatalmucormycosisinapatientwithchroniclymphocyticleukaemiatreatedwithzanubrutinibacasereportandreviewoftheliterature AT visentinandrea severefatalmucormycosisinapatientwithchroniclymphocyticleukaemiatreatedwithzanubrutinibacasereportandreviewoftheliterature AT carturanelisa severefatalmucormycosisinapatientwithchroniclymphocyticleukaemiatreatedwithzanubrutinibacasereportandreviewoftheliterature AT ruoccovaleria severefatalmucormycosisinapatientwithchroniclymphocyticleukaemiatreatedwithzanubrutinibacasereportandreviewoftheliterature AT trentinlivio severefatalmucormycosisinapatientwithchroniclymphocyticleukaemiatreatedwithzanubrutinibacasereportandreviewoftheliterature AT alaibacmauro severefatalmucormycosisinapatientwithchroniclymphocyticleukaemiatreatedwithzanubrutinibacasereportandreviewoftheliterature AT angeliniannalisa severefatalmucormycosisinapatientwithchroniclymphocyticleukaemiatreatedwithzanubrutinibacasereportandreviewoftheliterature |